clairop

How Long Does Budesonide Take to Work for Crohn's?

Some people feel budesonide within days, but trials judge it at week 8, when about half of mild to moderate ileocaecal Crohn's is in remission.

Clairop Team28 min read

Photo: Kelly Sikkema / Unsplash

The short answer

Budesonide (Entocort) is a gut-targeted steroid for mild to moderate Crohn's in the ileum and right colon. People describe feeling better anywhere from a day or two to about five weeks. Trials measure remission at week 8, where roughly 47% on budesonide reached it versus 22% on placebo. It is a short-course treatment, not a long-term maintenance drug.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

Budesonide usually takes somewhere between a few days and about five weeks to make a noticeable difference in Crohn's disease, and the trials that proved it works judge the result at week 8, not earlier. In those trials about half of people with mild to moderate disease in the ileum or right colon reached remission, so it helps many people but not everyone.

Budesonide (brand name Entocort EC, also sold as generic capsules) is a corticosteroid, a man-made version of the hormone cortisol that calms inflammation. It is built to act mainly in the last part of the small intestine (the ileum) and the first part of the colon on the right side (the ascending colon). Most of the drug is then broken down by the liver before it can circulate widely, which is why it tends to cause fewer steroid side effects than prednisone or prednisolone. This article covers how fast it works, what trial data say about weeks 2, 4 and 8, where it works, what the label warns about, and why it is a short-course medicine rather than a long-term one. It does not tell anyone how to take, taper, stop or switch it. Those decisions belong to your prescriber.

How long does budesonide take to work for Crohn's disease?

Budesonide is not an instant drug. People report relief within days to about a month, while the clinical trials measure success at week 8. The best evidence says roughly half of people with mild to moderate ileocaecal Crohn's reach remission by then, and a meaningful minority do not respond at all, which is why your team will want to check in rather than wait indefinitely.

Here is the honest shape of the timeline, split into what people say and what the research shows.

What people report. In an r/CrohnsDisease thread asking exactly this question (How long does budesonide take to work?), replies ranged from "noticed a change after about a month" to "it worked within a day or two while I waited for my biologic to be approved". Another thread (Budesonide Experience?) describes people who felt tired or agitated in the first week and then improved, some who felt worse again as the course wound down, and some for whom it never worked. A third (Budesonide, did it work?) is a reminder that not everyone gets relief, and that frustration is common. These are individual stories. They show the spread, not the odds.

What the research shows. The first large placebo-controlled trial of the Entocort-type capsule enrolled 258 people with active ileal or ileocaecal Crohn's and tested 3, 9 and 15 mg daily against placebo. The authors report a significant reduction in the Crohn's Disease Activity Index (CDAI) score after two weeks in the 9 mg and 15 mg groups, and the primary result at week 8 was remission in 51% on the 9 mg dose versus 20% on placebo (Greenberg 1994). In a trial against prednisolone, the capsule's once-daily regimen was described as "as promptly effective as prednisolone" (Campieri 1997).

So a first sign of improvement within the first two weeks is plausible, which matches what many people feel. But "first sign" is not "remission". Remission in these trials was a CDAI of 150 or less, a threshold many people take longer to reach, and the scored endpoint was week 8.

What do the trials say at week 2, 4 and 8?

By week 2 there is already a measurable fall in the average CDAI score on the 9 mg dose. The sturdiest number is at week 8, when remission rates in the main trials ranged from about 48% to 60% on budesonide. Pooling three placebo-controlled trials, 47% of people on 9 mg were in remission at week 8 versus 22% on placebo.

Here are the main controlled trials side by side. All used CDAI of 150 or less as remission, and all enrolled people with disease in the ileum and/or ascending colon.

TrialWho and how manyBudesonide resultComparison
Greenberg 1994258 people, active ileal or ileocaecal Crohn's51% remission at week 8 on 9 mgPlacebo 20% (Greenberg 1994; placebo figure from the label)
Rutgeerts 1994176 people, ileal or ileocaecal53% remission at week 10Prednisolone 66% (not statistically different) (Rutgeerts 1994)
Campieri 1997178 people, ileum and/or ascending colon60% at week 8 on once-daily dosingPrednisolone 60% (Campieri 1997)
Tremaine 2002 (US)200 people, CDAI 200 to 45048% once daily, 53% twice-daily splitPlacebo 33%, difference not significant (Tremaine 2002)
Cochrane pooled analysis3 placebo-controlled trials, 379 people47% (115 of 246)Placebo 22% (29 of 133), relative risk 1.93 (Rezaie 2015)

Three things are worth taking from this table.

First, the effect is real but not overwhelming. Even in positive trials, roughly half of people on budesonide were not in remission at week 8. In the original dose-ranging study, 46% of enrolled people left early, 96 of them because of insufficient therapeutic effect (Greenberg 1994). "It didn't work for me" is a common and legitimate outcome, not a failure on your part.

Second, trial results are not identical. The US trial found remission rates that did not differ significantly from placebo, although the average CDAI fell more in the budesonide groups (Tremaine 2002). That is why pooled analysis, which smooths over single-trial noise, is a better guide than any one study.

Third, "remission" is a high bar. The Rutgeerts trial reports that mean CDAI fell from 275 to 175 on budesonide, even though only 53% crossed the 150 line (Rutgeerts 1994). Many people improve a lot without being counted as in remission, and many of the people in these trials who felt better were still not at their baseline.

How does the CDAI work, and what is "remission" in these trials?

The CDAI is a scoring system that adds up stool frequency, abdominal pain, general wellbeing, extraintestinal symptoms, use of antidiarrheal drugs, an abdominal mass, body weight and hematocrit. A score of 150 or less counts as remission, and the budesonide label notes that it is based partly on what patients report (DailyMed label).

That has two consequences for you. The first is that the score leans on exactly what you can log yourself: how many loose stools you pass, how much pain you have and how you feel overall. The second is that it does not measure ulcers. In Crohn's, symptoms and inflammation can drift apart, which is why a symptom score is not the whole story. The related guide on how to tell if you're in a Crohn's flare explains why teams often add a stool calprotectin or imaging, and the same logic applies to judging whether a medicine has worked. Feeling better on budesonide is welcome. Whether the bowel itself has settled is a separate question for your gastroenterologist.

Why does budesonide only work in the ileum and right colon?

Budesonide is designed to land where Crohn's most often starts. Its capsule holds enteric-coated granules that dissolve above pH 5.5, which is typically around the end of the small bowel, and only 9% to 21% of an oral dose reaches the bloodstream because the liver clears most of it on first pass (DailyMed label).

That design is the whole reason it is an option for Crohn's in the lower small bowel. Two ideas are working together:

  • Topical delivery. The coating holds the drug back until it reaches the ileum and the start of the colon, so the highest concentrations meet the inflamed tissue.
  • First-pass metabolism. Whatever is absorbed passes through the liver, where an enzyme called CYP3A4 breaks most of it down. That keeps the amount reaching the rest of the body low.

The same label states that budesonide binds the glucocorticoid receptor with about 200 times the affinity of cortisol and 15 times that of prednisolone. It is a potent drug that is trying to stay local.

The consequence is that location decides whether it is a sensible choice. The label indications cover mild to moderate active Crohn's involving the ileum and/or the ascending colon. The British Society of Gastroenterology guideline recommends ileal-release budesonide for mild to moderate ileocaecal Crohn's disease (a strong recommendation, based on high-quality evidence) and adds that it helps disease reaching the proximal colon, while there is no evidence of benefit for more distal colonic inflammation (Lamb 2019). If your Crohn's is mainly in the left colon or rectum, or in the upper gut, this particular capsule was not designed for it.

This is one reason the answer to "how long does it take" varies so much between people. Someone with limited ileocaecal inflammation is exactly who the trials studied. Someone with widespread disease, or disease outside that area, is outside the evidence, and a lack of response may reflect that.

Is budesonide as strong as prednisone?

No. Budesonide is a little less effective than conventional steroids for inducing remission, particularly in more severe disease, but causes fewer steroid side effects and less suppression of the adrenal glands. A Cochrane analysis found remission in 52% on budesonide versus 61% on conventional steroids at week 8 (relative risk 0.85).

The details matter for anyone weighing it against prednisone:

  • Efficacy. In 8 trials (750 people), 52% of those on budesonide and 61% of those on conventional steroids were in remission at 8 weeks. In people with severe disease (CDAI above 300) budesonide did considerably worse (relative risk 0.52) (Rezaie 2015). The British guideline reaches the same conclusion, noting that budesonide is inferior to prednisolone in more severe disease (Lamb 2019).
  • Side effects. Steroid-related adverse events were less likely on budesonide (relative risk 0.64), and abnormal adrenal tests were also less likely (relative risk 0.65) (Rezaie 2015).
  • Speed. In the Rutgeerts trial prednisolone lowered CDAI more over 10 weeks, while the budesonide group had fewer steroid-associated side effects (29 versus 48 people) and less pituitary-adrenal suppression (Rutgeerts 1994).

In a plain-language sense, the trade is a slightly lower chance of full remission for a markedly gentler side-effect profile. A common theme in the Reddit threads is people describing budesonide as far easier to live with than prednisone, even when it makes them tired or agitated for a while. That matches the trial data on side effects, but how a drug feels is personal, and nothing here says which one you should be on. Whether budesonide or a stronger steroid fits your situation depends on where your disease is and how severe it is, which is a conversation for your gastroenterologist.

What are the side effects of budesonide for Crohn's?

Most side effects are mild and look like those of placebo, but budesonide is still a corticosteroid. The most common in the label's 8-week trials were headache (21%), respiratory infection (11%) and nausea (11%). Signs of excess steroid effect appeared in 34% of people on budesonide, compared with 27% on placebo and 48% on prednisolone.

The label's trial tables give a fair picture of what to expect. Percentages below are from the 8-week treatment trials at 9 mg a day (DailyMed label).

Side effectBudesonide 9 mgPlaceboPrednisolone
Headache21%18%21%
Respiratory infection11%7%14%
Nausea11%9%12%
Dizziness7%5%12%
Dyspepsia6%4%12%
Abdominal pain6%17%4%
Fatigue5%7%8%
Any sign of hypercorticism34%27%48%
Acne15%13%23%

Remember the label's own caution: rates from different trials cannot be compared directly, and your experience can differ. A few other points are worth knowing.

It can suppress your own cortisol. In a crossover study in healthy volunteers, five days of 9 mg budesonide reduced 24-hour cortisol exposure by 45%, compared with 78% for 20 mg of prednisolone (DailyMed label). Less suppression is not no suppression. The label says to monitor for signs of hypercorticism and adrenal axis suppression, and the Cochrane maintenance review found abnormal adrenal tests were more common on budesonide than placebo (Kuenzig 2014). The 2018 Cochrane update states plainly that the long-term effects on the adrenal axis and bone health remain unknown (Kuenzig 2018). This is one reason long courses are discouraged.

It is an immunosuppressant. The label warns that corticosteroids, including budesonide, can raise the risk of infection with any pathogen, can mask some signs of infection, and carry specific warnings about chickenpox, shingles and measles exposure, tuberculosis and hepatitis B screening (DailyMed label). Mention fevers or infections to your team rather than assuming they are part of the flare.

It can make you feel odd when you move from a stronger steroid. The label advises monitoring people who move from systemic steroids to budesonide, because withdrawal symptoms can appear, and it notes that allergies such as rhinitis and eczema that the systemic steroid was hiding can resurface (DailyMed label). People in the threads describe tiredness and agitation early on, and feeling worse as the course winds down. Those are experiences, not a medical explanation, but they are common enough to mention to your team.

Medicine and food interactions matter. Budesonide is broken down by CYP3A4. The label says to avoid CYP3A4 inhibitors such as ketoconazole and grapefruit juice, because a strong inhibitor caused an eight-fold increase in budesonide exposure (DailyMed label). Anyone with liver problems is a special case: the label notes higher exposure in moderate to severe hepatic impairment and says to avoid it in severe impairment. Tell your pharmacist about everything you take, including supplements and herbal products.

When should you call your gastroenterologist while on budesonide?

Call your gastroenterologist if you are not improving, if you are getting worse, or if you have any new symptom you are unsure about. Seek urgent help for severe abdominal pain, repeated vomiting, fever, heavy bleeding, signs of an allergic reaction, or signs of dehydration. Do not wait to see whether a worrying symptom settles.

Reasons to contact your team promptly:

  • No improvement, or a clear worsening, in stool frequency, pain or wellbeing after a few weeks on treatment
  • New blood in your stool, or more than before
  • Fever, chills or signs of any infection, including a sore throat, cough or a painful urinary tract
  • Symptoms that wake you at night
  • Unintended weight loss or being unable to eat
  • A swollen belly, or pain that is getting steadily worse
  • Vision changes, new muscle weakness, a rounded face, or marked mood changes
  • Exposure to chickenpox, shingles or measles
  • Any question about a new medicine, supplement or grapefruit product

Seek urgent or emergency help for: severe or worsening abdominal pain, repeated vomiting (particularly with no wind or stool passing), a high fever, a racing heart or feeling faint or confused, heavy rectal bleeding, a rash with swelling of the face or lips, or trouble breathing.

None of this is a reason to adjust your own medicine. Contact the clinician who prescribed it.

What if budesonide is not working?

Non-response is common and informative. If budesonide is not helping after the time your doctor expected, tell your gastroenterologist. Non-response is common, with roughly half of trial participants not reaching remission by week 8, and it can mean the inflammation is more extensive, more severe or in a different place than the capsule reaches. The next step is a prescriber decision.

A few questions are worth bringing to that appointment, rather than guessing:

  • Is the disease where we thought it was? If the inflammation extends beyond the ileum and right colon, this capsule may not reach it.
  • Is it truly inflammation causing my symptoms? Narrowing (a stricture), bacterial overgrowth, bile acid diarrhea and IBS-type symptoms can feel like a flare but respond differently. Our guide to how to tell if you're in a Crohn's flare covers these look-alikes and the tests that separate them.
  • Is a stool calprotectin, blood test, ultrasound or scope due? Objective tests tell you more than a feeling does.
  • Is my dose and formulation what you intended? In the Reddit thread about timelines, several people noticed they were unsure whether their bottle matched the plan in their clinic letter. If anything on the label or the letter does not match what you were told, ask your pharmacist or clinic to confirm. Do not work it out yourself.
  • Is this course a bridge to something else? Many people use budesonide while a longer-term treatment is arranged. A common theme in r/CrohnsDisease is using it to cover the gap while a biologic is approved by insurance or while it starts working. The patient information site IBD Relief says it is "generally only used for short periods of time", either to induce remission or to help you feel better while longer-term maintenance treatments start to work (IBD Relief). The trials we reviewed did not test "bridging" as a strategy, so treat the practice as common clinical use rather than a proven approach.

If the answer is that your disease needs stronger or longer-term treatment, our guide on whether to start biologics for mild Crohn's disease walks through how doctors weigh that decision, and the broader list of questions to ask your doctor about Crohn's disease is a useful companion.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Why is budesonide not a long-term maintenance treatment?

Budesonide helps people stay well for a few months at most. It delays relapse slightly, but it does not keep Crohn's in remission over a year, and extended use carries steroid-related risks. The British guideline recommends avoiding corticosteroids as maintenance therapy in Crohn's because of toxicity and lack of efficacy.

That might sound at odds with the fact that the label does include a maintenance indication, so here is how the two fit together.

What the label says. For adults in remission after an 8-week course, the label supports maintenance treatment for up to 3 months and states that continued treatment beyond 3 months has not been shown to provide substantial clinical benefit (DailyMed label). In the pooled maintenance trials, the median time to relapse was 268 days on budesonide 6 mg versus 154 days on placebo, and 28% on budesonide had lost symptom control at 3 months versus 45% on placebo (DailyMed label).

What the trials found beyond 3 months. The predetermined pooled analysis of four trials (380 people) reached the same median-time numbers, with a significant reduction in relapse at 3 and 6 months but not at 12 months (Sandborn 2005).

What the Cochrane review concluded. Across 12 studies (1,273 people), 6 mg daily was no more effective than placebo at 3, 6 or 12 months. At 12 months, 55% on budesonide were still in remission versus 48% on placebo (a difference that could be chance), while abnormal adrenal stimulation tests were more frequent on budesonide (relative risk 2.88). The authors concluded that budesonide is not effective for maintenance, particularly beyond three months after induction (Kuenzig 2014).

What about safety over a year? The picture is more nuanced than "dangerous". A pooled safety analysis of five 1-year trials found an adverse-event profile similar to placebo, with only rare serious steroid-related events, although there were more cutaneous steroid symptoms such as acne and bruising on budesonide, and adrenal function was more often abnormal at 13 weeks but not at 52 weeks (Lichtenstein 2009). In the label's long-term tables, bruising (10% versus 4%) and acne (10% versus 2%) were more common on 6 mg than on placebo (DailyMed label).

Putting that together: the drug is reasonably well tolerated for a year in trials, but it does not do enough to justify years of use. That is why guidance steers toward a different maintenance plan. The British guideline's wording is direct: it recommends that systemic or locally acting corticosteroids be avoided as maintenance therapy in Crohn's because of toxicity and lack of efficacy (strong recommendation, high-quality evidence) (Lamb 2019).

Some people in the Reddit threads describe being on budesonide for many months, sometimes alongside a biologic, with the prescriber watching blood sugar and bone health. That happens in real clinics, and it can be a deliberate decision by a specialist. It is also outside what the trials established, so it is a conversation, not a default.

Does budesonide prevent Crohn's coming back after surgery?

Mostly no. In a randomized trial of 129 people who had bowel resection for ileal or ileocaecal Crohn's, budesonide 6 mg daily did not reduce endoscopic recurrence overall at 3 or 12 months. A subgroup operated on for active disease had lower recurrence at 12 months (32% versus 65%), but that was not seen in people operated on for scarring.

This is a useful reminder that budesonide's job is to quiet active inflammation in a particular area, not to protect against Crohn's returning. If you have had surgery, how to prevent recurrence is its own discussion with your team, and our post on a food and symptom diary after a Crohn's bowel resection covers what to log. For the trial itself, see Hellers 1999.

Does budesonide help with mouth ulcers or other symptoms outside the gut?

There is no good trial evidence for that. The trials scored bowel symptoms and general wellbeing, not mouth ulcers, joint pain or eye problems, and the drug is designed to act locally in the gut. One Reddit parent asked whether it helped their daughter's mouth ulcers, and the replies did not settle it, which is typical.

If you have ulcers, joint pain, eye redness or skin changes alongside your gut symptoms, those are worth raising with your team, because they can point to disease activity that a gut-targeted capsule would not touch. Our guides on mouth ulcers with Crohn's and joint pain with Crohn's go through what is known.

Should you change what you eat while on budesonide?

Budesonide does not come with a special diet, apart from avoiding grapefruit juice, and food during a flare is its own question. How you eat while treatment is taking effect depends on your symptoms and any narrowing in your bowel, and your team or a dietitian who knows IBD can tailor it.

A common theme in the Reddit threads is advice to eat low fiber during a flare, delivered with great certainty. That may suit some people, particularly those with a stricture, but it is not a universal rule and it is not part of the budesonide label. Our deeper guide on what to eat during a Crohn's flare-up sets out what the evidence supports and where it is thin, including why restrictive diets can backfire. The practical point for this article is that diet is an add-on to a medical plan, not a substitute for one.

How can you track whether budesonide is working?

Track the same things the trials scored, every day, in one place. A short daily log is the most useful thing you can bring to a review. It turns "I think I'm a bit better" into numbers, and it mirrors what the trials scored: stool frequency, stool consistency, pain and wellbeing. Add sleep, mood and energy, because those are the effects people most often describe on this drug. If you were on conventional prednisone before, our guide to prednisone's psychological side effects covers how those mood and sleep effects compare.

Here is a simple set of things to write down each day, starting before the first capsule if you can:

What to logWhy it helps
Number of stools and how loose they areClosest match to the CDAI's main components
Abdominal pain, 0 to 10Another core CDAI element
General wellbeing, 0 to 10The third patient-reported CDAI element
Blood or mucusA flag for your team
Sleep and moodCommon early effects people describe
Energy and appetiteTracks recovery and side effects
Date of each treatment change, as directed by your clinicianLets you see what lined up with what
Any other medicine, supplement or grapefruit exposureInteractions can matter

Two things make a log far more useful. First, keep a few days of baseline before any change if you can, so you have something to compare against. Second, resist the urge to judge a single day. A rough Tuesday after a better week is normal, and a seven-day average tells you more than any one morning.

If you would rather not keep this on paper, Clairop lets you log symptoms and medication in a few taps and turns them into a one-page report for your gastroenterologist, and its method page explains why it waits for repeated observations before calling anything a pattern. It cannot tell you whether budesonide is working. That judgment belongs to your clinician, ideally backed by an objective test. A sheet of A4 does the same job for tracking.

If the log points to a flare building rather than settling, our guide on how to track symptoms during a flare covers what to add, and what to track in an IBD symptom diary has a fuller list.

What does a realistic budesonide course look like?

For many people a course looks like a slow improvement over the first month, a possible dip in energy or mood early on, a review with the gastroenterologist around the end of the planned treatment, and a plan for what follows. The plan after budesonide matters as much as the course itself, because the drug does not hold remission.

Here is a general, non-prescriptive picture drawn from the label, the guidelines and what people describe:

  1. Before starting. Your team confirms where your disease is (ileum and right colon is the target), how severe it is, and what other medicines, liver issues or infection history might matter. They may screen for infections such as tuberculosis or hepatitis B, in line with the label's warnings.
  2. The first week or two. Some people feel better quickly. Others feel tired, agitated, headachey or nauseated. Trials show a measurable fall in average CDAI by week 2 on the 9 mg dose, but a fall in an average is not the same as every person improving.
  3. Weeks 3 to 8. This is the window the trials measured. Remission, where it happens, is typically judged by week 8. A decision about what comes next is usually made with your team around then, not left to drift.
  4. The end of the course. How the course ends, including any reduction in dose, is the prescriber's call and depends on the individual plan. Do not work it out from a thread.
  5. The plan after. Because budesonide does not hold remission for a year, the useful question to ask early is "what is the longer-term plan if this works, and if it does not?" Many people are on, or are about to start, a different maintenance treatment.

A good question to take to your first appointment is one you can ask without any medical knowledge: "How will we know whether this has worked, and what happens next either way?"

What about children and teenagers?

The US label covers children aged 8 to 17 who weigh more than 25 kg for active mild to moderate disease, and notes that young people have slightly higher systemic exposure and more cortisol suppression than adults (DailyMed label). In a pediatric label study, the share of children with a normal response to an ACTH challenge fell from 73% at baseline to 6% at week 8 on budesonide, though the group was small (16 children at week 8).

That is a good reason to leave dosing and monitoring entirely to the pediatric gastroenterology team, who will also weigh growth and bone health. If you are a parent, our guide to helping a teenager with Crohn's disease covers the wider picture.

Common myths about budesonide

"If it hasn't worked in two weeks, it never will." Not quite. A fall in average CDAI appears by week 2 in the trial, but the endpoint was week 8, and people in the threads describe benefit arriving after four or five weeks. The right move is to tell your team where you are, not to set your own deadline.

"It's a safe steroid, so it can be used forever." The label and the guidelines say otherwise. It is gentler than prednisone, not harmless, and it has not been shown to maintain remission beyond about three months.

"It works anywhere in the gut." It is designed for the ileum and ascending colon. Disease elsewhere is outside the evidence for this capsule, and the colon-targeted tablets used in ulcerative colitis are a different product.

"A lower dose just takes longer." We could not find evidence that a lower dose simply works more slowly. In the dose-ranging trial, the 3 mg group was not statistically different from placebo while 9 mg was (Greenberg 1994). If you are unsure whether you have the dose your clinician intended, confirm it with them or your pharmacist rather than guessing.

"Feeling better means the inflammation is gone." In Crohn's, symptoms and inflammation do not always move together, which is why your team may recheck with a calprotectin or other test after a course.

"Grapefruit is just a rumor." It is on the label. The label says to avoid grapefruit juice for the duration of treatment (DailyMed label).

The bottom line

Budesonide often starts to help within days to weeks, and the trial answer is week 8, when about half of people with mild to moderate disease in the ileum and right colon are in remission versus about a fifth on placebo. It is gentler than prednisone, less effective in severe disease, and not a maintenance medicine. The most useful thing you can do is bring a few weeks of numbers, plus your questions about what happens next, to the person who prescribed it.

How this article was built. The efficacy and safety figures come from the randomized trials, Cochrane reviews, the British Society of Gastroenterology guideline and the US prescribing label cited above, each opened and checked. Reddit threads are used only to describe what people report, never as evidence that a drug works. The article was not clinically reviewed by a named clinician.

This article is general information, not medical advice. Clairop is not affiliated with any drug manufacturer. Talk to your gastroenterologist or pharmacist about your own treatment.

Frequently asked questions

How long does budesonide take to work for Crohn's disease?
People report feeling a difference anywhere from a day or two to about five weeks. Trials do not judge it that early. They count remission (a Crohn's Disease Activity Index score of 150 or less) at week 8, when about 47% of people on budesonide were in remission versus 22% on placebo in a Cochrane pooled analysis. Your gastroenterologist decides when to judge your response.
How can you tell if budesonide is working?
Look for a trend in the same things the trials scored: stool frequency, how loose the stools are, abdominal pain and general wellbeing. A daily log shows a slow shift that a single day will not. Symptoms alone can mislead in Crohn's, so ask your team whether a stool calprotectin or other test should confirm what you feel.
What if budesonide has not worked after a few weeks?
Tell your gastroenterologist rather than waiting it out or changing anything yourself. Budesonide does not help everyone: in the landmark dose-ranging trial, 96 of the 258 people enrolled left early because of insufficient effect. It is also less effective than conventional steroids in severe disease, so lack of response is useful information for your team.
Does budesonide work for Crohn's in the colon?
Only in part of it. The capsules are designed to release in the ileum and the right (ascending) colon, and trials enrolled people with disease there. The British Society of Gastroenterology notes budesonide helps disease reaching the proximal colon but there is no evidence of benefit in more distal colonic inflammation, so location matters before it is chosen.
How long can you stay on budesonide for Crohn's?
The US label describes treatment courses of up to 8 weeks for active disease and, for adults in remission, maintenance for up to 3 months, saying longer use has not been shown to give substantial benefit. In practice, some people use it for longer under specialist supervision. How long you take it is a decision for your prescriber, not a thread.
Why is budesonide not used for long-term maintenance in Crohn's?
It prolongs time to relapse a little but does not hold remission over a year. A Cochrane review found 6 mg daily no better than placebo at 3, 6 or 12 months, with more abnormal adrenal tests. The British Society of Gastroenterology recommends avoiding corticosteroids as maintenance in Crohn's because of toxicity and lack of efficacy.
Is budesonide safer than prednisone?
Generally it causes fewer steroid side effects, because the liver breaks most of it down on first pass (oral bioavailability is 9% to 21%). In a Cochrane analysis, steroid-related adverse events were less likely than with conventional steroids (relative risk 0.64). But it is not harmless: it can suppress adrenal function and carries infection warnings. Safer does not mean side-effect free.
Can you have grapefruit juice while taking budesonide?
The US label says to avoid grapefruit juice for the duration of treatment, and to avoid CYP3A4 inhibitors such as ketoconazole. Those can raise the amount of budesonide in your blood, and ketoconazole caused an eight-fold increase in exposure in the label data. Tell your pharmacist about every medicine and supplement you take, including over-the-counter ones.
What are the most common side effects of budesonide for Crohn's?
In the label's 8-week trials the most common were headache (21%), respiratory infection (11%), nausea (11%), back pain, dizziness, dyspepsia, abdominal pain, flatulence, vomiting and fatigue. Signs of too much steroid, such as acne, easy bruising and a rounded face, were reported in 34% on budesonide versus 27% on placebo and 48% on prednisolone.
What is the best app for tracking how well budesonide is working?
The best tool is the one you will fill in daily, whether paper, a spreadsheet or an app. What matters is logging stool frequency, pain, wellbeing, sleep, mood and the dates of any treatment changes. Clairop does this and turns the log into a one-page report for your gastroenterologist, but it cannot say whether a medicine is working.

Sources

  1. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994;331(13):836-41. doi:10.1056/NEJM199409293311303
  2. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994;331(13):842-5. doi:10.1056/NEJM199409293311304
  3. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut. 1997;41(2):209-14. doi:10.1136/gut.41.2.209
  4. Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002;97(7):1748-54. doi:10.1111/j.1572-0241.2002.05835.x
  5. Rezaie A, Kuenzig ME, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH, et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2015;2015(6):CD000296. doi:10.1002/14651858.CD000296.pub4
  6. Kuenzig ME, Rezaie A, Kaplan GG, Otley AR, Steinhart AH, Griffiths AM, et al. Budesonide for the induction and maintenance of remission in Crohn's disease: systematic review and meta-analysis for the Cochrane Collaboration. J Can Assoc Gastroenterol. 2018;1(4):159-73. doi:10.1093/jcag/gwy018
  7. US National Library of Medicine. DailyMed: budesonide delayed-release capsules (Entocort EC) prescribing information, set id 3a18d5a7-04c5-4137-8155-70a8adc0a48b. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a18d5a7-04c5-4137-8155-70a8adc0a48b
  8. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484
  9. Kuenzig ME, Rezaie A, Seow CH, Otley AR, Steinhart AH, Griffiths AM, et al. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2014;2014(8):CD002913. doi:10.1002/14651858.CD002913.pub3
  10. Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005;100(8):1780-7. doi:10.1111/j.1572-0241.2005.41992.x
  11. Lichtenstein GR, Bengtsson B, Hapten-White L, Rutgeerts P. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Aliment Pharmacol Ther. 2009;29(6):643-53. doi:10.1111/j.1365-2036.2008.03891.x
  12. Hellers G, Cortot A, Jewell D, Leijonmarck CE, Lofberg R, Malchow H, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology. 1999;116(2):294-300. doi:10.1016/s0016-5085(99)70125-3

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools